Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C Virus
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir used for patients infected with HCV genotype 1 in daily practice in Japan.
- Trial name
- NCT02629172
- Where
- 388 sites in Japan
- Volunteers
- 3,043 people
- Sponsor
- AbbVie
Hepatitis C, Substance Use Disorders
Eliminating HCV in Rural South Carolina Utilizing NP Led Mobile Clinics and Virtual Care Coordination
Up to 150 individuals with current hepatitis C (HCV) will be recruited from mobile health clinics in rural South Carolina - sites will be selected based on HCV prevalence rates and lack of current HCV screening/treatment…
- Trial name
- STAT-C (NCT05369507)
- Testing
- Virtual Care Coordination
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Prisma Health-Upstate
Hepatitis C, Substance Use Disorders
Opportunstic Hepatitis C Virus Treatment
The project will assess the effect of opportunistically treating hepatitis C virus (HCV) infection immediately when HCV-infected people who inject drugs are hospitalized for acute care in psychiatric, interdisciplinary…
- Trial name
- Opportuni-C (NCT04220645)
- Testing
- Opportunstic treatment, Standard of care
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- University Hospital, Akershus
Chronic Hepatitis C
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.
- Trial name
- NCT00968357
- Testing
- SCV-07
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- SciClone Pharmaceuticals
Chronic Hepatitis C
Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy
The objective of this study is to better understand the influence of insulin resistance upon treatment response in hepatitis C virus treated with PEG Intron and Rebetol.
- Trial name
- NCT00351871
- Testing
- PEG-Intron Plus REBETOL
- Volunteers
- 400 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Hepatitis C
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection…
- Trial name
- NCT07040319
- Testing
- Glecaprevir/pibrentasvir
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
The purposes of this study are: 1. To test if 36 weeks of standard dose of ribavirin with PEGASYS® is non-inferior to standard dose of 48 weeks of ribavirin with PEGASYS® in SVR for patients with RVR and HVL 2.
- Trial name
- NCT01937728
- Testing
- A: Peg-interferon alpha-2a & Ribavirin, B: Peg-interferon alpha-2a & Ribavirin, C: Peg-interferon alpha-2a & Ribavirin
- Where
- Taiwan
- Volunteers
- 542 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C
The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda…
- Trial name
- NCT02063607
- Testing
- Peginterferon lambda
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Antiviral Drug Adverse Reaction
Effect Of DAAs For Treatment Of HCV On Normal Kidney
The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.
- Trial name
- NCT03296930
- Testing
- Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir
- Volunteers
- 100 people
- Sponsor
- Assiut University
Chronic Hepatitis C
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the…
- Trial name
- FUSION (NCT01604850)
- Testing
- SOF, RBV
- Where
- 67 sites in United States, Canada and 2 more
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Hepatitis C
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025. The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.
- Trial name
- HOSPI-VHC (NCT04405024)
- Testing
- Hepatitis C testing
- Where
- 4 sites in France
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Hepatitis C
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN…
- Trial name
- ATTAIN (NCT01485991)
- Testing
- TMC435, TVR
- Where
- 137 sites in United States, Argentina and 22 more
- Volunteers
- 771 people
- Sponsor
- Janssen R&D Ireland
Chronic Hepatitis C Infection
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with ACH-0143102 and ribavirin in genotype 1b (GT1b), treatment-naive, hepatitis C virus (HCV) participants.
- Trial name
- NCT01700179
- Testing
- ACH-0143102, Ribavirin
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)
Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron and Rebetol (according to the label) and the patient assistance program, which…
- Trial name
- NCT00723879
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908), Patient assistance program
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hemoglobinopathies
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT03149289
- Testing
- Antiviral drugs
- Volunteers
- 168 people
- Sponsor
- Società Italiana Talassemie ed Emoglobinopatie
Hepatitis C
Hepatitis C Antiviral Resistance in African-Americans
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not…
- Trial name
- NCT00038974
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 401 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HCV Infection, Liver Transplantation
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
The purpose of this study is to determine whether a human monoclonal antibody against Hepatitis C (MBL-HCV1) is effective in preventing detectable levels of Hepatitis C virus in patients undergoing liver transplantation due to…
- Trial name
- MBL-HCV1 (NCT01121185)
- Testing
- MBL-HCV1
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- MassBiologics
Hepatitis C, Depression
Reducing Depressive Symptoms During HCV Therapy: A Randomized Study
The purpose of this study is to conduct a randomized controlled trial of an 8-visit non-pharmacologic group intervention in reducing the severity of depressive symptoms in veterans who receive IFN and ribavirin for the treatment…
- Trial name
- NCT00495768
- Testing
- Group Training
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- South Texas Veterans Health Care System
Hepatitis C, Pregnancy
Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic
The first part of this study will investigate the incidence of Hepatitis C in pregnant women attending an inner city health clinic in downtown Toronto.
- Trial name
- NCT00348660
- Where
- Canada
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Hepatitis C, Chronic
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
This 4 arm study will compare the safety and tolerability of HCV polymerase inhibitor pro-drug in combination with PEGASYS +/- COPEGUS with the standard of care therapy of PEGASYS + COPEGUS, in treatment-naive patients with CHC…
- Trial name
- NCT00377182
- Testing
- Copegus, PEGASYS, RO5024048 1500mg
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 107 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.